Increasing Emphasis on Combined Therapeutics to Enhance Pipeline for Diabetes and Obesity Drugs, says Review

Published Date : Dec 05, 2016

Albany, NY, Dec 05, 2016: The report provides a comprehensive overview of the diabetes and obesity drug development pipeline. It offers qualitative insights into therapeutics and product development by stage, companies, and institutes. It profiles the key companies involved in the drug development market for both diabetes (type 1 and type 2) and obesity. A detailed description of dormant projects, discontinued products, and product development milestones form an important part of the study. 

Obesity and diabetes are chronic diseases and major public health problems. Diabetes is broadly classified into type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM). A steady rise in T2DM occurrence across the globe is intrinsically associated with the rapid global rise in obesity. With the increasing incidence of obesity, it is on the brink of being considered a global epidemic and there is a growing pool of patients requiring pharmacotherapeutic treatment. 

Anti-obesity drugs may potentially work through one of following three mechanisms:

  • Interference with nutrients absorption
  • Appetite Suppression
  • Metabolism enhancement of nutrients 

Drugs approved for treating obesity usually result in weight loss of about 2-5 kg in addition to placebo. However, historically, anti-obesity therapeutics had limited adoption due to safety concerns. Both obesity and diabetes products are commonly linked to cardiovascular adverse events, and there long term use is further compounded by concerns regarding cancer development. 

For Sample Copy, click here: 

The market for diabetes drugs is set to boom, driven by the success of a number of T2DM pipeline products. While products for obesity available at present do not have a large market presence, there is a plethora of these products in the pipeline. The combined therapeutics for obesity and diabetes offers a strong pipeline, representing a large share of the overall metabolic disorders therapy area.  Most of these drugs are biologics and small molecules, which indicates the trend of the overall pharmacotherapeutic market. 

Invokana, which is marketed by Johnson & Johnson, is one of the key drugs available for the treatment of the disease cluster. Another drug, Metformim is approved for type 2 diabetes and overweight subjects. Exenatide, which is a single-agent drugs in late stage development and has been validated to cause weight loss in patients with obesity and type 2 diabetes. Rimonabent is a selective blocker antagonist of the cannabinoid-1 receptor, which is associated with favorable effects on C-reactive protein, serum lipids, waist circumference, weight, and glycemic control in type 2 diabetes. However, this drug is linked to an increased incidence of anxiety, depression, and nausea. 

To order report Call Toll Free: 866-997-4948 or send an email on